• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Stronger Guidance, Dividend Steadiness, and FDA Win Might Change The Case For Investing In Johnson & Johnson (JNJ)

    Simply Wall St·07/18/2026 21:28:19
    Listen to the news
    • In the past week, Johnson & Johnson reported second-quarter 2026 results showing sales of US$25.31 billion and net income of US$5.53 billion, raised its full-year 2026 sales outlook to between US$100.8 billion and US$101.4 billion, affirmed a third-quarter dividend of US$1.34 per share, and received U.S. FDA approval for its dual-energy THERMOCOOL SMARTTOUCH SF ablation platform.
    • These updates highlight a company balancing growing Innovative Medicine revenues and continued dividend increases with legal setbacks in talc litigation and uneven MedTech performance.
    • We’ll now examine how stronger earnings guidance amid MedTech underperformance and ongoing talc litigation affects Johnson & Johnson’s broader investment narrative.

    Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

    Johnson & Johnson Investment Narrative Recap

    To own Johnson & Johnson today, you need to believe that Innovative Medicine can offset pressures in MedTech and from ongoing litigation, while the company maintains disciplined capital allocation. The latest quarter, with higher 2026 sales guidance to US$100.8 billion–US$101.4 billion and steady net income, supports that thesis but does not remove the near term overhang from talc verdicts, which remain a key risk to watch.

    The reaffirmed third quarter dividend of US$1.34 per share, on top of years of increases, is especially relevant here. It signals that management is comfortable returning cash to shareholders even as talc cases progress and MedTech execution is uneven, which matters if you see the main catalyst as earnings stability and cash generation rather than a quick resolution of legal issues.

    Yet beneath the higher sales outlook, the persistent talc litigation and its growing judgments are issues investors should understand before they...

    Read the full narrative on Johnson & Johnson (it's free!)

    Johnson & Johnson's narrative projects $116.6 billion revenue and $26.9 billion earnings by 2029. This requires 6.6% yearly revenue growth and a $5.9 billion earnings increase from $21.0 billion.

    Uncover how Johnson & Johnson's forecasts yield a $252.87 fair value, in line with its current price.

    Exploring Other Perspectives

    JNJ 1-Year Stock Price Chart
    JNJ 1-Year Stock Price Chart

    Some of the most optimistic analysts were already assuming revenue could reach about US$125.7 billion and earnings US$29.6 billion by 2029, a far more bullish view than consensus, and your own take on today’s guidance and talc risks might shift how realistic that path now looks.

    Explore 7 other fair value estimates on Johnson & Johnson - why the stock might be worth as much as 49% more than the current price!

    Form Your Own Verdict

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    No Opportunity In Johnson & Johnson?

    Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.